Telmisartan + cilnidipine
Telmisartan + cilnidipine has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 9, 2026: “Hypertension Management Beyond Blood Pressure Control in India: An Expert Consensus on Angiotensin II Receptor Blocker and Calcium Channel Blocker…”.
See all 1 papers on telmisartan + cilnidipine
What did studies of telmisartan + cilnidipine find?
2Studies of telmisartan + cilnidipine measured 2 outcomes; the most studied are proteinuria (1 study) and blood pressure (1).
Proteinuria
downin humans1
1 study
Proteinuria
downin humans1
Telmisartan + cilnidipine decreases proteinuria in humans (individuals with CVD, CKD, and T2DM).
“Evidence showed improved BP control, reduced proteinuria, and organ protection in individuals with CVD, CKD, and T2DM.”
Reviewindividuals with CVD, CKD, and T2DM
Cureus
Blood pressure
upin humans1
1 study
Blood pressure
upin humans1
Telmisartan + cilnidipine improves blood pressure in humans (individuals with CVD, CKD, and T2DM).
“Evidence showed improved BP control, reduced proteinuria, and organ protection in individuals with CVD, CKD, and T2DM.”
Reviewindividuals with CVD, CKD, and T2DM
Cureus